.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Teva
UBS
Moodys
Cerilliant
Healthtrust
Cipla
Cantor Fitzgerald
Harvard Business School
Merck

Generated: June 23, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,872,147

« Back to Dashboard

Claims for Patent: 5,872,147

Title: Use of oxandrolone in the treatment of chronic obstructive pulmonary disease
Abstract:The subject invention provides a method of treating a symptom associated with chronic obstructive pulmonary disease in a patient suffering from chronic obstructive pulmonary disease which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of improving functional capacity and/or pulmonary function in a patient suffering from chronic obstructive pulmonary disease which comprises administering a therapeutically effective amount of an oxandrolone to the patient.
Inventor(s): Bowen; Robert E. (Martinsburg, WV)
Assignee: Bio-Technology General Corp. (Iselin, NJ)
Application Number:08/986,015
Patent Claims: 1. A method of treating a symptom associated with chronic obstructive pulmonary disease in a patient suffering from chronic obstructive pulmonary disease which comprises administering a therapeutically effective amount of an oxandrolone to the patient.

2. A method according to claim 1, wherein the symptom is cachexia, muscle wasting or involuntary weight loss.

3. A method of improving pulmonary function in a patient suffering from chronic obstructive pulmonary disease which comprises administering a therapeutically effective amount of an oxandrolone to the patient.

4. A method of improving functional capacity in a patient suffering from chronic obstructive pulmonary disease which comprises administering a therapeutically effective amount of an oxandrolone to the patient.

5. A method according to claims 1, 3, or 4 wherein the amount of the oxandrolone is about 1-100 mg/day.

6. A method according to claim 5 wherein the amount of the oxandrolone is about 10-20 mg/day.

7. A method according to claim 5 wherein the amount of the oxandrolone is about 0.2 mg/kg/day.

8. A method according to claims 1, 3 or 4 wherein the oxandrolone is administered orally.

9. A method according to claims 1, 3, or 4 wherein the oxandrolone is injected.

10. A method according to claims 1, 3, or 4 wherein the oxandrolone is in a solid dosage form.

11. A method according to claims 1, 3, or 4 wherein the oxandrolone is in a liquid dosage form.

12. A method according to claims 1, 3, or 4 wherein the oxandrolone is in a sustained-release formulation.

13. A method of improving pulmonary function in a patient suffering from adult respiratory distress syndrome which comprises administering a therapeutically effective amount of an oxandrolone to the patient.

14. A method of improving functional capacity in a patient suffering from adult respiratory distress syndrome which comprises administering a therapeutically effective amount of an oxandrolone to the patient.

15. A method according to claims 1, 3, 4, 13 or 14, wherein the oxandrolone is 17.alpha.-methyl-17.beta.-hydroxy-2-oxa-5.alpha.-androstan-3-one.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
UBS
Queensland Health
Deloitte
Express Scripts
US Department of Justice
Daiichi Sankyo
Argus Health
Healthtrust
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot